Category: Press Release

Download PDF – Patients Treated with Tivozanib in TIVO-3 Study Demonstrated Over 20 Months Median DOR; OS Relative to Sorafenib Continues to Improve with Longer Follow-up – – Analysis of TEAEs in TIVO-3 Study Shows Longer Time to Onset and Fewer Dose Reductions for TEAEs for Tivozanib Compared to Sorafenib – – Data to be

Download PDF – U.S. Commercial Launch Underway with Fully Deployed Sales Force Following FDA Approval of FOTIVDA® (tivozanib) on March 10, 2021 – – FOTIVDA Net Product Revenue of $1.1 Million from Initial Distributor Orders in the Last Week of Q1; All Distributors Have Placed Reorders for Q2 – – Entered Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb for

Download PDF BOSTON–(BUSINESS WIRE)–May 3, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report first quarter 2021 financial results on Monday, May 10, 2021. AVEO’s management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 10, 2021, to discuss the financial results and provide

Download PDF BOSTON–(BUSINESS WIRE)–Apr. 16, 2021– AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors. A widely recognized clinical oncologist with a specialty in head and neck cancer, Dr. Cullen is the Marlene and Stewart Greenebaum Distinguished Professor in Oncology and director

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 29, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines to include FOTIVDA® (tivozanib) as a recommended regimen for subsequent therapy. The subsequent therapy category follows the first-line treatment regimen recommendations for patients with clear cell histology renal cell carcinoma (ccRCC). On March 10,

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 26, 2021– AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an additional 900,000 shares, at a price to the public of $8.00 per share. The aggregate gross proceeds

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 23, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. The gross proceeds to AVEO from the offering are expected to be $48.0 million before deducting underwriting discounts and commissions and offering

Download PDF – FOTIVDA is the First Therapy Approved for Adults with Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies – – AVEO ACE Patient Support Program in Place to Assist with Access, Affordability, and Treatment Adherence – BOSTON–(BUSINESS WIRE)–Mar. 22, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that FOTIVDA® (tivozanib) is now commercially

Download PDF BOSTON–(BUSINESS WIRE)–Mar. 22, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock. All of the shares

Download PDF – FOTIVDA® (tivozanib) Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies; AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 – – Entered Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb for Planned Pivotal Phase 3 TiNivo-2 Study of